Shares in Roche dropped more than 5% on March 9 after the Swiss pharmaceutical company announced that its experimental oral breast cancer drug giredestrant failed to show effectiveness in newly diagnosed patients.
Shares in Roche Holding (ROG.S) rose about 2% on Monday, outperforming a largely unchanged European healthcare index, after the Swiss drugmaker announced it is advancing its experimental obesity drug, CT-388, to a late-stage clinical trial.
09 Mar 2026-13:54
22 Sep 2025-13:48
